Cartesian Therapeutics, Inc. (FRA:1S70)
Germany · Delayed Price · Currency is EUR | Market Cap | 166.97M -17.1% |
| Revenue (ttm) | 1.29M +44.0% |
| Net Income | -132.95M |
| EPS | -5.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 5.55 |
| Previous Close | 5.40 |
| Day's Range | 5.35 - 5.55 |
| 52-Week Range | 4.68 - 9.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyosi... [Read more]
Financial Performance
In 2025, Cartesian Therapeutics's revenue was $2.80 million, a decrease of -92.81% compared to the previous year's $38.91 million. Losses were -$130.30 million, 68.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseas...
Cartesian Therapeutics announces positive retreatment data on Descartes-08
Cartesian Therapeutics (RNAC) announced additional positive retreatment data of its lead investigational asset, Descartes-08, in patients with generalized myasthenia gravis, being presented during the...
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune disea...
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027
Cartesian Therapeutics Quarterly report: Q2 2026
Cartesian Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cartesian Therapeutics Earnings release: Q2 2026
Cartesian Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseas...
Cartesian Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum, elected three directors for terms expiring in 2029, and saw overwhelming approval for executive compensation and auditor ratification, each with 99% support. No questions were raised by stockholders during the Q&A.
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans ...
Cartesian Therapeutics secures up to $150M financing from K2 HealthVentures
Cartesian Therapeutics (RNAC) announced that it has entered into an agreement with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in life scien...
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune disease...
Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $25 from $30 and keeps a Buy rating on the shares. The firm delayed the company’s launch timing…
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple pa...
Cartesian Therapeutics Quarterly report: Q1 2026
Cartesian Therapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.
Cartesian Therapeutics Earnings release: Q1 2026
Cartesian Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Cartesian Therapeutics management to meet with BTIG
Meeting to be held in New York on April 30 at 6 pm hosted by BTIG.
Cartesian Therapeutics Proxy statement: Proxy filing
Cartesian Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Cartesian Therapeutics Proxy statement: Proxy filing
Cartesian Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald upgraded Cartesian Therapeutics (RNAC) to Overweight from Neutral.
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald upgraded Cartesian Therapeutics (RNAC) to Overweight from Neutral with a $16 price target Cartesian had no major surprises in its Q4 earnings report, as catalyst timing remains the…
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
Reports FY25 revenue $2.797M, consensus $1.97M. “Building on a productive year, we look forward to a potentially transformative 2026 as we advance Descartes-08 across several autoimmune indications,” ...
Cartesian Therapeutics Earnings release: Q4 2025
Cartesian Therapeutics released its Q4 2025 earnings on March 9, 2026, summarizing the period's financial results.
Cartesian Therapeutics Annual report: Q4 2025
Cartesian Therapeutics has published its Q4 2025 annual report on March 9, 2026.